19/03/2026 GSK announced FDA approval of linerixibat for adult patients with PBC GSK announced FDA approval of linerixibat for adult patients with PBC ( Ref ) GSK announced that the US FDA had approved Lynavoy (linerixibat; an IBAT inhibitor) for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC) The approval was based on data from the global Phase 3, GLISTEN/ NCT04950127 trial The trial met both primary and key secondary endpoints,

26/02/2026 GSK’s linerixibat accepted for Priority review by China’s NMPA in patients with PBC Boehringer acquired an exclusive license for a novel oral therapeutics program for immune diseases from Sitryx Argenx announced topline results from Phase 3 trial of VYVGART in Ocular myasthenia gravis Soligenix received a positive opinion from the EMA on its request for orphan drug designation for SGX945 for the treatment of behçet's disease GSK’s linerixibat accepted for Priority